Literature DB >> 25424202

Autoimmunity Links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes Following Campylobacter jejuni Infection in a Rat Model.

Mark Pimentel1, Walter Morales, Venkata Pokkunuri, Constantinos Brikos, Sun Moon Kim, Seong Eun Kim, Konstantinos Triantafyllou, Stacy Weitsman, Zachary Marsh, Emily Marsh, Kathleen S Chua, Shanthi Srinivasan, Gillian M Barlow, Christopher Chang.   

Abstract

BACKGROUND: Acute gastroenteritis can precipitate irritable bowel syndrome (IBS) in humans. Cytolethal distending toxin is common to all pathogens causing gastroenteritis. Its active subunit, CdtB, is associated with post-infectious bowel changes in a rat model of Campylobacter jejuni infection, including small intestinal bacterial overgrowth (SIBO). AIM: To evaluate the role of host antibodies to CdtB in contributing to post-infectious functional sequelae in this rat model.
METHODS: Ileal tissues from non-IBS human subjects, C. jejuni-infected and control rats were immunostained with antibodies to CdtB, c-Kit, S-100, PGP 9.5 and vinculin. Cytosolic and membrane proteins from mouse enteric neuronal cell lysates were immunoprecipitated with anti-CdtB and analyzed by mass spectrometry. ELISAs were performed on rat cardiac serum using CdtB or vinculin as antigens.
RESULTS: Anti-CdtB antibodies bound to a cytosolic protein in interstitial cells of Cajal (ICC) and myenteric ganglia in C. jejuni-infected and naïve rats and human subjects. Mass spectrometry identified vinculin, confirmed by co-localization and ELISAs. Anti-CdtB antibodies were higher in C. jejuni-infected rats (1.27 ± 0.15) than controls (1.76 ± 0.12) (P < 0.05), and rats that developed SIBO (2.01 ± 0.18) vs. rats that did not (1.44 ± 0.11) (P = 0.019). Vinculin expression levels were reduced in C. jejuni-infected rats (0.058 ± 0.053) versus controls (0.087 ± 0.023) (P = 0.0001), with greater reductions in rats with two C. jejuni infections (P = 0.0001) and rats that developed SIBO (P = 0.001).
CONCLUSIONS: Host anti-CdtB antibodies cross-react with vinculin in ICC and myenteric ganglia, required for normal gut motility. Circulating antibody levels and loss of vinculin expression correlate with number of C. jejuni exposures and SIBO, suggesting that effects on vinculin are important in the effects of C. jejuni infection on the host gut.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25424202     DOI: 10.1007/s10620-014-3435-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  13 in total

1.  Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome.

Authors:  A Lupascu; M Gabrielli; E C Lauritano; E Scarpellini; A Santoliquido; G Cammarota; R Flore; P Tondi; P Pola; G Gasbarrini; A Gasbarrini
Journal:  Aliment Pharmacol Ther       Date:  2005-12       Impact factor: 8.171

2.  Guidelines--Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders.

Authors: 
Journal:  J Gastrointestin Liver Dis       Date:  2006-09       Impact factor: 2.008

3.  Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis.

Authors:  Rebecca M Lovell; Alexander C Ford
Journal:  Clin Gastroenterol Hepatol       Date:  2012-03-15       Impact factor: 11.382

4.  Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome.

Authors:  M Pimentel; E J Chow; H C Lin
Journal:  Am J Gastroenterol       Date:  2000-12       Impact factor: 10.864

Review 5.  Small intestinal bacterial overgrowth: what it is and what it is not.

Authors:  Eamonn M M Quigley
Journal:  Curr Opin Gastroenterol       Date:  2014-03       Impact factor: 3.287

6.  Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS.

Authors:  Derek Yu; Frank Cheeseman; Stephen Vanner
Journal:  Gut       Date:  2010-11-26       Impact factor: 23.059

7.  A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease.

Authors:  W Kruis; C Thieme; M Weinzierl; P Schüssler; J Holl; W Paulus
Journal:  Gastroenterology       Date:  1984-07       Impact factor: 22.682

8.  Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.

Authors:  M Majewski; R W McCallum
Journal:  Adv Med Sci       Date:  2007       Impact factor: 3.287

9.  Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin.

Authors:  L Cuoco; M Salvagnini
Journal:  Minerva Gastroenterol Dietol       Date:  2006-03

10.  New clinical method for distinguishing D-IBS from other gastrointestinal conditions causing diarrhea: the LA/IBS diagnostic strategy.

Authors:  Mark Pimentel; Laura Hwang; Gil Y Melmed; Kimberly Low; Eric Vasiliauskas; Andrew Ippoliti; Janet Yang; Sheila Lezcano; Jeffrey L Conklin; Ara Sahakian
Journal:  Dig Dis Sci       Date:  2009-01-24       Impact factor: 3.199

View more
  23 in total

1.  Understanding and Managing IBS and CIC in the Primary Care Setting.

Authors:  Brooks D Cash
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-05

2.  Autoimmunity as a Potential Cause of Post-Infectious Gut Dysmotility: A Longitudinal Observation.

Authors:  Ali Rezaie; Mark Pimentel; Erica Cohen
Journal:  Am J Gastroenterol       Date:  2017-04       Impact factor: 10.864

3.  Second-Generation Biomarker Testing for Irritable Bowel Syndrome Using Plasma Anti-CdtB and Anti-Vinculin Levels.

Authors:  Walter Morales; Ali Rezaie; Gillian Barlow; Mark Pimentel
Journal:  Dig Dis Sci       Date:  2019-05-31       Impact factor: 3.199

4.  Advances in IBS 2016: A Review of Current and Emerging Data.

Authors:  Philip S Schoenfeld
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-08

Review 5.  The Traveling Microbiome.

Authors:  Mark S Riddle; Bradley A Connor
Journal:  Curr Infect Dis Rep       Date:  2016-09       Impact factor: 3.725

6.  Diagnostics: Filling in the missing pieces.

Authors:  Alla Katsnelson
Journal:  Nature       Date:  2016-05-19       Impact factor: 49.962

7.  Anti-vinculin antibodies in scleroderma (SSc): a potential link between autoimmunity and gastrointestinal system involvement in two SSc cohorts.

Authors:  Yossra Suliman; Suzanne Kafaja; Sunny J Oh; Mohamed Alemam; Gianluca Bagnato; Giuseppina Abignano; Ram Raj Singh; Gillian Barlow; Xiaochen Liu; Isela Valera; Walter Morales; Ali Rezaie; Mark Pimentel; Francesco Del Galdo; Daniel E Furst
Journal:  Clin Rheumatol       Date:  2020-11-24       Impact factor: 2.980

8.  Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome.

Authors:  Ali Rezaie; Sung Chul Park; Walter Morales; Emily Marsh; Anthony Lembo; Jae Hak Kim; Stacy Weitsman; Kathleen S Chua; Gillian M Barlow; Mark Pimentel
Journal:  Dig Dis Sci       Date:  2017-04-27       Impact factor: 3.199

Review 9.  Small intestinal bacterial overgrowth in systemic sclerosis.

Authors:  Kathleen Morrisroe; Murray Baron; Tracy Frech; Mandana Nikpour
Journal:  J Scleroderma Relat Disord       Date:  2019-07-29

10.  Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects.

Authors:  Mark Pimentel; Walter Morales; Ali Rezaie; Emily Marsh; Anthony Lembo; James Mirocha; Daniel A Leffler; Zachary Marsh; Stacy Weitsman; Kathleen S Chua; Gillian M Barlow; Enoch Bortey; William Forbes; Allen Yu; Christopher Chang
Journal:  PLoS One       Date:  2015-05-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.